Nanoscale drug delivery systems and the blood-brain barrier

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 795-811

  Alyautdin, Renad ^a   Khalin, Igor ^b   Nafeeza, Mohd Ismail ^a   Haron, Muhammad Huzaimi ^a   Kuznetsov, Dmitry ^c  

^a UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^b NATIONAL DEFENCE UNIVERSITY OF MALAYSIA   (Malaysia)

^c PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

apoE; Blood brain barrier; CNS; Drug targeting; Liposomes; Nanoparticles

Indexed keywords

COLLOID; LIPOSOME; NANOPARTICLE;

ACTIVE TRANSPORT; ANATOMY AND HISTOLOGY; ANIMAL; BLOOD BRAIN BARRIER; CHEMISTRY; COLLOID; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HUMAN; MEDICINAL CHEMISTRY; NANOMEDICINE; NANOTECHNOLOGY; PHYSIOLOGY;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; CHEMISTRY, PHARMACEUTICAL; COLLOIDS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY;

EID: 84893713788     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S52236     Document Type: Review

References (179)

1. Mullard A. 2012 FDA drug approvals. Nat Rev Drug Discov. 2013; 12(2):87-90.
2. Pan A, Sun Q, Okereke OI, Rexrode KM, Hu FB. Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. JAMA. 2011;306(11):1241-1249.
3. Matschay A, Nowakowska E, Hertmanowska H, Kus K, Chubak A. Cost analysis of therapy for patients with multiple sclerosis (MS) in Poland. Pharmacol Rep. 2008;60:632-644.
4. Trahan MA, Kahng S, Fisher AB, Hausman NL. Behavior-analytic research on dementia in older adults. J Appl Behav Anal. 2011;44: 687-691.
5. Ribatti D, Nico B, Crivellato E, Artico M. Development of the blood-brain barrier: a historical point of view. Anat Rec B New Anat. 2006;289(1):3-8.
6. Lewandowsky M., Zur Lehre von der Cerebrospinalflüssigkeit. [On the cerebrospinal fluid]. X Z Klin Med. 1900;40:480-494. German.
7. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther. 2004;104: 29-45.
8. Begley DJ. The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol. 1996;4: 136-146.
9. Bernacki J, Dobrowolska A, Nierwińska K, Malecki A. Physiology and pharmacological role of the blood-brain barrier. Pharmacol Rep. 2008;60:600-622.
10. Farell CL, Pardridge WM. Blood-brain-barrier glucose transporter is asymmetrically distributed on brain capillary endothelial luminal and abluminal membranes: an electronic microscopic immunogold study. Proc Natl Acad Sci U S A. 1999;88:5779-5783.
11. Vorbrodt AW. Morphological evidence of the functional polarization of brain microvascular endothelium. In: Pardridge WM, editor. The Blood-Brain Barrier: Cellular and Molecular Biology. Raven Press (New York, NY); 1999.
12. Abbott NJ. Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell Mol Neurobiol. 2005;25:5-22.
13. Abbott NJ. Comparative physiology of the blood-brain barrier. In: Bradbury, MWB, editor. Physiology and Pharmacology of the BloodBrain Barrier. Heidelberg: Springer-Verlag; 1992:371-396.
14. Hosoya K, Ohtsuki S, Terasaki T. Recent advances in the brain-to-blood efflux transport across the blood-brain barrier. Int J Pharm. 2002;248: 15-29.
15. Abbott NJ, Bundgaard M, Cserr HFJ. Tightness of the blood-brain barrier and evidence for brain interstitial fluid flow in the cuttlefish, Sepia officinalis. J Physiol. 1985;368:213-226.
16. Matter K, Balda MS. Signalling to and from tight junctions. Nat Rev Mol Cell Biol. 2003;4:225-236.
17. Hawkins BT, Davis TP, The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57:173-185.
18. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7:41-53.
19. Aguzzi A, Barres BA, Bennett ML. Microglia: scapegoat, saboteur, or something else? Science. 2013;339(6116):156-161.
20. Daneman R, Rescigno M, The gut immune barrier and the blood-brain barrier: are they so different? Immunity. 2009;31:722-735.
21. Chen Y, Liu L. Modern methods for delivery of drugs across the bloodbrain barrier. Adv Drug Deliv Rev. 2012;64(7):640-665.
22. Correale J, Villa A. Cellular elements of the blood-brain barrier. Neurochem Res. 2009;34:2067-2077.
23. Cornford E, Hyman S. Localization of brain endothelial luminal and abluminal transporters with immunogold electron microscopy. NeuroRx. 2005;2:27-43.
24. Abbott NJ, Patabendige A, Dolman D, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37:13-25.
25. Begley DJ, Brightman MW. Structural and functional aspects of the blood-brain-barrier. In: Prokai L, Prokai-Tatrai K, editors. Peptide Transport and Delivery into the Central Nervous System (Progress in Drug Research). Basel: Birkhäuser Verlag; 2003;61:39-78.
26. Wolburg H, Noell S, Mack A, Wolburg-Buchholz K, Fallier-Becker P. Brain endothelial cells and the glio-vascular complex. Cell Tissue Res. 2009;335:75-96.
27. Alavijeh MS, Chishty M, Qaiser MZ, Palmer AM. Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. NeuroRx. 2005;2:554-571.
28. Hawkins RA, O'Kane RL, Simpson IA. Structure of the blood-brain barrier and its role in the transport of amino acids. J Nutr. 2006;136: 218S-226S.
29. Borges-Walmsley MI, McKeegan KS, Walmsley AR. Structure and function of efflux pumps that confer resistance to drugs. Biochem J. 2003;376:313-338.
30. Sharom FJ. The P-glycoprotein multidrug transporter. Essays Biochem. 2011;50(1):161-178.
31. Chen ZS, Lee K, Walther S, et al. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res. 2002;62(11): 3144-3150.
32. Imaoka T, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol. 2007;71(2):619-627.
33. Hasegawa M, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Multidrug resistance-associated protein 4 is involved in the urinary excretion of hydrochlorothiazide and furosemide. J Am Soc Nephrol. 2007;18(1):37-45.
34. Ci L, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y. Involvement of MRP4 (ABCC4) in the luminal efflux of ceftizoxime and cefazolin in the kidney. Mol Pharmacol. 2007;71(6): 1591-1597.
35. Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res. 2002;62(17):5035-5040.
36. Robey RW, Honjo Y, Morisaki K, et al. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer. 2003;89(10):1971-1978.
37. Burger H, Van Tol H, Boersma AW, et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004;104(9):2940-2942.
38. Honjo Y, Hrycyna CA, Yan QW, et al. Acquired mutations in the MXR/ BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCPoverexpressing cells. Cancer Res. 2001;61(18):6635-6639.
39. Litman T, Brangi M, Hudson E, et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci. 2000;113(Pt 11):2011-2021.
40. Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci. 2000;89:1371-1388.
41. Bradbury MW, Stubbs J, Hughes IE, Parker P. The distribution of potassium, sodium, chloride and urea between lumbar cerebrospinal fluid and blood serum in human subject. Clin Sci. 1963;25:97-105.
42. Gingrich MB, Traynelis SF. Serine proteases and brain damage - is there a link? Trends Neurosci. 2000;23:399-407.
43. Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chem Acta. 2002;310:173-186.
44. Clark DE. In silico prediction of blood-brain barrier permeation. Drug Discov Today. 2003;8:927-933.
45. Vorbrodt AW, Dobrogowska DH, Tarnawski M. Immunogold study of interendothelial junction-associated and glucose transporter proteins during postnatal maturation of the mouse blood-brain barrier. J Neurocytol. 2001;30:705-716.
46. Birnbaum MJ, Haspel HC, Rosen OM. Cloning and characterization of cDNA encoding the rat brain glucose-transporter protein. Proc Natl Acad Sci U S A. 1986;83:5784-5788.
47. Simpson IA, Carruthers A, Vannucci J. Supply and demand in cerebral energy metabolism: the role of nutrient transporters. J Cereb Blood Flow Metab. 2007;27:1766-1791.
48. Klepper J, Voit T. Facilitated glucose transporter protein type 1 (GLUT1) deficiency syndrome: impaired glucose transport into brain a review. Eur J Pediatr. 2002;161:295-304.
49. Gerhard DZ, Leino RL, Taylor WE, Borson ND, Dreves LR. GLUT1 and GLUT3 gene expression in gerbil brain following brief ischemia: an in situ hybridization study. Brain Res Mol Brain Res. 1994;25: 313-322.
50. Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM. Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc Natl Acad Sci U S A. 1999;96:12079-12084.
51. Borst P, Evers R, Kool M, Wijnholds J. A family of drug t{stroke}ransporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000;92:1295-1302.
52. Gleeson MP. Generation of a set of simple, interpretable ADMET rules of thumb. J Med Chem. 2008;51:817-834.
53. Rip J, Schenk GJ, de Boer AG. Differential receptor-mediated drug targeting to the diseased brain. Expert Opin Drug Deliv. 2009;6: 227-237.
54. Sauer I, Dunay IR, Weisgraber K, Bienert M, Dathe M. An apolipoprotein E-derived peptide mediates uptake of sterically stabilized liposomes into brain capillary endothelial cells. Biochemistry. 2005;44: 2021-2029.
55. Kim WK, Corey S, Alvarez X, Williams K. Monocyte/macrophage traffic in HIV and SIV encephalitis. J Leukoc Biol. 2003;74(5):650-656.
56. Pawlowski NA, Kaplan G, Abraham E, Cohn ZA. The selective binding and transmigration of monocytes through the junctional complexes of human endothelium. J Exp Med. 1988;168(5):1865-1882.
57. Park K. Trojan monocytes for improved drug delivery to the brain. J Control Release. 2008;132(2):75.
58. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2:3-14.
59. Pardridge WM. A morphological approach to the analysis of blood-brain-barrier transport function. In: Paulson O, Knudsen G, Moos T, editors. Brain Barrier Systems. Copenhagen: Munkgaard; 1999:13-54.
60. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis. 2010;37:48-57.
61. Polly JW, Olson KL, Chism JP. Getting into the brain. Approaches to enhance brain drug delivery. CNS Drug. 2009;23:35-58.
62. ++ ion in capillary endothelial cells. Acta Neurochir Suppl. 1997;70:231-233.
63. Kroll RA, Pagel MA, Muldoon LL, Roman-Goldstein S, Fiamengo SA, Neuwelt EA. Improving drug delivery to intracerebral tumor and surrounding brain in a rodent model: a comparison of osmotic versus bradykinin modification of the blood-brain and/or blood-tumor barriers. Neurosurgery. 1998;43:879-886.
64. Regioli D, Barabé J. Pharmacology of bradykinin and related kinins. Pharmacol Rev. 1980;32:1-46.
65. Rhaleb N, Télémaque S, Rouisson N, et al. Structure-activity studies of bradykinin and related peptides. B2-receptor antagonists. Hypertension. 1991;17:107-115.
66. Matsukado K, Sugita M. Intracarotid low dose bradykinin infusion selectively increases tumor permeability through activation of bradykinin B2 receptors in malignant gliomas. Brain Res. 1998;4:10-15.
67. Borlongan CV, Emerich DF. Facilitation of drug entry into the CNS via transient permeation of blood brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport. Brain Res Bull. 2003:297-306.
68. Sanovich E, Bartus RT, Friden PM, Dean RL, Le HQ, Brightman MW. Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7. Brain Res. 1995:125-135.
69. Kuo YC, Lee CL. Methylmethacrylate-sulfopropylmethacrylate nanoparticles with surface RMP-7 for targeting delivery of antiretroviral drugs across the blood-brain barrier. Colloids Surf B Biointerfaces. 2012;90:75-82.
70. Zhang XB, Yuan S, Lei PC, Hou XP. Therapeutic efficiency of amphotericin B liposome modified by RMP-7 to transport drug across blood brain barrier. Yao Xue Xue Bao. 2004;39(4):292-295. Chinese.
71. Sheikov N, McDannold N, Vykhodtseva N, Jolesz F, Hynynen K. Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles. Ultrasound Med Biol. 2004;30(7):979-989.
72. Kinoshita M, McDannold N, Jolesz F, Hynynen K. Targeted delivery of antibodies through the blood-brain barrier in MRI-guided focused ultrasound. Biochem Biophys Res Commun. 2006;340:1085-1090.
73. Shimamura M, Sato N, Taniyama Y, et al. Development of efficient plasmid DNA transfer into adult rat central nervous system using microbubble-enhanced ultrasound. Gene Ther. 2004;11:1532-1539.
74. Cho CW, Liu Y, Cobb W, et al. Ultrasound induced mild hyperthermia as a novel approach to increase drug uptake in brain microvessel endothelial cells. Pharm Res. 2002;19(8):1123-1129.
75. Hsu PH, Wei KC, Huang CY, et al. Noninvasive and targeted gene delivery into the brain using microbubble-facilitated focused ultrasound. PLoS One. 2013;8(2):e57682.
76. Stam R. Electromagnetic fields and the blood-brain barrier. Brain Res Rev. 2010;65:80-97.
77. Zhou JX, Ding GR, Zhang J, Zhou YC, Zhang YJ, Guo GZ. Detrimental effect of electromagnetic pulse exposure on permeability of in vitro blood-brain-barrier model. Biomed Environ Sci. 2013;26(2): 128-137.
78. Kuo YC, Lu CH. Modulation of efflux proteins by electromagnetic field for delivering azidothymidine and saquinavir into the brain. Colloids Surf B Biointerfaces. 2012;91:291-295.
79. Tabatabaei SN, Duchemin S, Girouard H, Martel S. Towards MRnavigable nanorobotic carriers for drug delivery into the brain. IEEE Int Conf Robot Autom. 2012:727-732.
80. Bachmeier CJ, Miller DW. A fluorometric screening assay for drug efflux transporter activity in the blood-brain barrier. Pharm Res. 2005;22:113-121.
81. Greig NH, Genka S, Daly EM, Sweeney DJ, Rapoport SI. Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration. Cancer Chemother Pharmacol. 1990;25:311-319.
82. Lipinski CA, Lombardo F, Dominy BW, Feene PG. Experimental and computational approach to estimate solubility and permeability in drug discovery and development setting. Adv Drug Deliv Rev. 2007;59: 155-188.
83. Walker A, Tyor W. Neurosarcoidosis. Curr Treat Options Neurol. 2001;3:529-535.
84. Kammerer M, Rassner MP, Freiman TM, Feuerstein TJ. Effects of antiepileptic drugs on GABA release from rat and human neocortical synaptosomes. Naunyn Schmiedebergs Arch Pharmacol. 2011;384:47-57.
85. Taylor CP, Gee NS, Su TZ, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 1998;29:233-249.
86. Yoshizumi M, Parker RA, Eisenach JC, Hayashida K. Gabapentin inhibits γ-amino butyric acid release in the locus coeruleus but not in the spinal dorsal horn after peripheral nerve injury in rats. Anesthesiology. 2012;116:1347-1353.
87. Negri L, Lattanzi R, Tabacco F, Scolaro B, Rocchi R. Glycodermorphins: opioid peptides with potent and prolonged analgesic activity and enhanced blood-brain barrier penetration. Br J Pharmacol. 1998;124:1516-1522.
88. Denora N, Trapani A, Laquintana V, Lopedota A, Tropani G. Recent advances in medicinal chemistry and pharmaceutical technologystrategies for drug delivery to the brain. Curr Top Med Chem. 2009;9: 182-196.
89. Spudich A, Kilic E, Xing H, et al. Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat Neurosci. 2006;9:487-488.
90. Yang Y, Rosenberg GA. Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke. 2011;42:3323-3328.
91. Hayashi K, Pu H, Tian J, et al. HIV-Tat protein induces P-glycoprotein expression in brain microvascular endothelial cells. J Neurochem. 2005;93:1231-1241.
92. Kabanov AV, Batrakova EV, Miller DW. Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. Adv Drug Deliv Rev. 2003;55:151-164.
93. Laquintana V, Trapani A, Denora N, Wang F, Gallo GM, Tripani G. New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv. 2009;6:1017-1032.
94. Moghimi SM, Hunter AC, Murray JC. Long-circulating and targetspecific nanoparticles: theory to practice. Pharmacol Rev. 2001;53: 1283-1318.
95. Ogawa K, Furumoto K, Takakura Y, Hoshida M, Higaki K, Kimura T. Surface hydrophobicity of particles is not necessarily the most important determinant in their in vivo disposition after intravenous administration in rats. J Control Release. 2001;77:191-198.
96. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv. 2007;4:297-305.
97. Voinea M, Simionescu M. Designing of 'intelligent' liposomes for efficient delivery of drugs. J Cell Mol Med. 2002;6:465-474.
98. Schmidt J, Metselaar JM, Wauben MH, Toyka KV, Storm G, Gold R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain. 2003;126:1895-1904.
99. Huang FY, Chen WJ, Lee WY, Lo ST, Lee TW, Lo JM. In vitro and in vivo evaluation of lactoferrin-conjugated liposomes as a novel carrier to improve the brain delivery. Int J Mol Sci. 2013;14(2): 2862-2874.
100. Pinzón-Daza M, Garzón R, Couraud P, et al. The association of statins plus LDL receptor-targeted liposome-encapsulated doxorubicin increases in vitro drug delivery across blood-brain barrier cells. Br J Pharmacol. 2012;167(7):1431-1447.
101. Liu L, Venkatraman SS, Yang YY, et al. Polymeric micelles anchored with TAT for delivery of antibiotics across the blood-brain barrier. Biopolymers. 2008;90:617-623.
102. Gaillard PJ, Brink A, de Boer AG. Diphtheria toxin receptor-targeted brain drug delivery. Int Congr Ser 2005;1277:185-198.
103. Nishikawa K, Asai T, Shigematsu H, et al. Development of anti-HBEGF immunoliposomes for the treatment of breast cancer. J Control Release. 2012;160(2):274-280.
104. Chekhonin VP, Baklaushev VP, Yusubalieva GM, et al. Targeted delivery of liposomal nanocontainers to the peritumoral zone of glioma by means of monoclonal antibodies against GFAP and the extracellular loop of Cx43. Nanomedicine. 2012;8(1):63-70.
105. O'Donnell ME, Lam TI, Tran LQ, Foroutan S, Anderson SE. Estradiol reduces activity of the blood-brain-barrier Na-K-Cl contransporter and decreases edema formation in permanent middle cerebral artery occlusion. J Cereb Blood Flow Metab. 2006;26:1234-1249.
106. Krauze, Michal T, et al. Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts. Neuro-oncology. 2007;9: 393-403.
107. Hau P, Fabel K, Baumgart U, et al. Pegylated liposomal doxorubicinefficacy in patients with recurrent high-grade glioma. Cancer. 2004;100(6):1199-1207.
108. Soni V, Kohli DV, Jain SK. Transferrin-conjugated liposomal system for improved delivery of 5-fluorouracil to brain. J Drug Target. 2008;16:73-78.
109. Shi N, Boado RJ, Pardridge WM. Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharm Res. 2001;18(8):1091-1095.
110. Zhang Y, Calon F, Zhu C, et al. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum Gene Ther. 2003;14(1):1-12.
111. Zhang Y, Jeong Lee H, Boado RJ, Pardridge WM. Receptor-mediated delivery of an antisense gene to human brain cancer cells. J Gene Med. 2002;4(2):183-194.
112. Boado RJ, Pardridge WM. The Trojan horse liposome technology for nonviral gene transfer across the blood-brain barrier. J Drug Deliv. 2011;2011:296151.
113. Xie Y, Ye L, Zhang X, et al. Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: in vitro and in vivo studies. J Control Release. 2005;105(1-2):106-119.
114. Li W, Zhou Y, Shao N, Chao B, Wang X, Kong P. Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. Environ Toxicol Pharmacol. 2012;34: 272-279.
115. Ishii T, Asai T, Oyama D, et al. Amelioration of cerebral ischemiareperfusion injury based on liposomal drug delivery system with asialo-erythropoietin. J Control Release. 2012;160:81-87.
116. Ramos-Cabrer P, Agulla J, Argibay B, Pérez-Mato M, Castillo D. Serial MRI study of the enhanced therapeutic effects of liposome-encapsulated citicoline in cerebral ischemia. Int J Pharm. 2011;405:228-233.
117. Shaw GJ, Meunier JM, Huang SL, Lindsell CJ, McPherson DD, Holland CK. Ultrasound-enhanced thrombolysis with tPA-loaded echogenic liposomes. Thromb Res. 2009;124:306-310.
118. Laing ST, Moody M, Smulevitz B, et al. Ultrasound-enhanced thrombolytic effect of tissue plasminogen activator-loaded echogenic liposomes in an in vivo rabbit aorta thrombus model brief report. Arterioscler Thromb Vasc Biol. 2011;31:1357-1359.
119. Ying X, Wen H, Lu WL, Du J, Guo J, Tian WJ. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release. 2010;141:183-192.
120. Zhao XB, Muthusamy N, Byrd JC, Lee RJ. Cholesterol as a bilayer anchor for PEGylation and targeting ligand in folate-receptor targeted liposomes. J Pharm Sci. 2007;96:2424-2435.
121. Banks WA, Robinson SM, Nath A. Permeability of the blood-brain barrier to HIV-1 Tat. Exp Neurol. 2005;193:218-227.
122. Strazza M, Pirrone V, Wigdahl B, Nonnemacher MR. Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier. Brain Res. 2011;1399:96-115.
123. Toborek M, Lee YW, Flora G, et al. Mechanisms of the blood-brain barrier disruption in HIV-1 infection. Cell Mol Neurobiol. 2005;25: 181-199.
124. Torchilin VP. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev. 2008;60(4-5): 548-558.
125. Qin Y, Zhang Q, Chen H, et al. Comparison of four different peptides to enhance accumulation of liposomes into the brain. J Drug Target. 2012;20(3):235-245.
126. Spuch C, Navarro C. Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer's disease and Parkinson's disease). J Drug Deliv. 2011;2011:1-12.
127. Qin Y, Chen H, Zhang Q, et al. Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals. Int J Pharm. 2011;420(2):304-312.
128. Craparo EF, Bond ML, Pitarresi G, Cavallaro G. Nanoparticulate systems for drug delivery and targeting to the central nervous system. CNS Neurosci Ther. 2011;17:670-677.
129. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloid Surf. 2010;75:1-18.
130. Pinto Reis C, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomed-Nanotechnol. 2006;2:8-21.
131. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv. 2001;47:65-81.
132. Kreuter J, Alyautdin R, Kharkevich D, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 1995;674:171-174.
133. Kreuter J, Alyautdin RN. Using nanoparticles to target drugs to the central nervous system. In: Begley DJ, Bradbury MW, Kreuter J, editors. The Blood-Brain Barrier and Drug Delivery to the CNS. New York, NY: Marcel Dekker, Inc; 2000:205-223.
134. Schroeder U, Schroeder H, Sabel BA. Body distribution of 3H-labelled dalargin bound to poly(butyl cyanoacrylate) nanoparticles after iv injections to mice. Life Sci. 2000;66:495-502.
135. Alyautdin RN, Tezikov EB, Ramge P, Kharkevich DA, Begley DJ, Kreuter J. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study, J Microencapsul. 1998;15:67-74.
136. Basel AA, et al. Transport prozerina v golovnoy mozg pri pomoshchi poli(butil)tsianoakrilatnykh nanochastits, pokrytykh polisorbatom-80. [Transport of neostigmine to the brain using poly(butyl)cyanoacrylate nanoparticles coated with polysorbate-80] Rossijskij medicinskij žurnal. 2006;4:28-32. Russian.
137. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. Delivery of loperamide across the blood-brain barrier with poly-sorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res. 1997;14:325-328.
138. Steiniger SC, Kreuter J, Khalansky AS, et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer. 2004;109:759-767.
139. Kurakhmaeva KB, Kijindijkhasvili IA, Petrov VE, et al. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles, J Drug Target. 2009;17:564-574.
140. Wohlfart S, Gelperina S, Kreuter J. Transport of drugs across the bloodbrain barrier by nanoparticles. J Control Release. 2012;161.2:264-273.
141. Michaelis K, Hoffmann MM, Dreis S, et al. Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther. 2006;317:1246-1253.
142. Kreuter J. Influence of the surface properties on nanoparticlemediated transport of drugs to the brain. J Nanosci Nanotechnol. 2004;4:484-488.
143. Kreuter J, Ramge P, Petrov V, et al. Direct evidence that polysorbate-80-coated poly (butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res. 2003;20:409-416.
144. Kreuter J, Shamenkov D, Petrov V. Apolipoprotein mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target. 2002;10:317-325.
145. Wilson B, Samanta MK, Santhi K, Kumar KP. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease. Brain Res. 2008;1200:159-168.
146. Wang CX, Huang LS, Hou LB, Jiang L, Yan ZT, Wang YL. Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model. Brain Res. 2009;1261:91-99.
147. Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm. 2008;70:75-84.
148. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res. 1999;16(10):1564-1569.
149. Kreuter J, Gelperina S. Use of nanoparticles for cerebral cancer. Tumori. 2008;94:271-277.
150. Olivier JC. Drug transport to brain with targeted nanoparticles. NeuroRx. 2005;2:108-119.
151. Pardridge W. Molecular Trojan horses for blood-brain barrier drug delivery. Curr Opin Pharmacol. 2006;6:494-500.
152. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin-and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm. 2009;71.2:251-256.
153. Ulbrich K, Knobloch T, Kreuter J. Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB). J Drug Target. 2011;19:125-132.
154. Rao KV, Reddy MK, Horning JL, Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials. 2008;29:4429-4438.
155. Tian XH, Wei F, Wang TX, et al. In vitro and in vivo studies on gelatinsiloxane nanoparticles conjugated with SynB peptide to increase drug delivery to the brain. Int J Nanomedicine. 2012;7:1031-1041.
156. Guarnieri D, Falanga A, Muscetti O, et al. Shuttle-mediated nanoparticle delivery to the blood brain barrier. Small. 2013;9(6):853-862.
157. Skrlj N, Drevenšek G, Hudoklin S, Romih R, Curin Šerbec V, Dolinar M. Recombinant single-chain antibody with the Trojan peptide penetratin positioned in the linker region enables cargo transfer across the blood-brain barrier. Appl Biochem Biotechnol. 2013;169(1):159-169.
158. Gopal V, Xavier J, Dar GH, Jafurulla M, Chattopadhyay A, Rao NM. Targeted liposomes to deliver DNA to cells expressing 5-HT receptors. Int J Pharm. 2011;419:347-354.
159. Mora M, Sagrista ML, Trombetta D, et al. Design and characterization of liposomes containing long-chain N-acylPEs for brain delivery: penetration of liposomes incorporating GM1 into the rat brain. Pharm Res. 2002;19(10):1430-1438.
160. Nowacek AS, Miller RL, McMillan J, et al. NanoART synthesis, characterization, uptake, release and toxicology for human monocytemacrophage drug delivery. Nanomedicine (Lond). 2009;4(8):903-917.
161. Gendelman HE, Kabanov A, Linder J. The promise and perils of CNS drug delivery: a video debate. J Neuroimmune Pharmacol. 2008;3(2):58.
162. Batrakova EV, Gendelman HE, Kabanov AV. Cell-mediated drugs delivery. Expert Opin Drug Deliv. 2011;8(4):415-443.
163. Afergan E, Epstein H, Dahan R, et al. Delivery of serotonin to the brain by monocytes following phagocytosis of liposomes. J Control Release. 2008;132(2):84-90.
164. Batrakova EV, Li S, Reynolds AD, et al. A macrophage-nanozyme delivery system for Parkinson's disease. Bioconjug Chem. 2007;18(5): 1498-1506.
165. Martins S, Tho I, Reimold I, et al. Brain delivery of camptothecin by means of solid lipid nanoparticles: formulation design, in vitro and in vivo studies. Int J Pharm. 2012;439(1-2):49-62.
166. Yusuf M, Khan M, Khan RA, Ahmed B. Preparation, characterization, in vivo and biochemical evaluation of brain targeted Piperine solid lipid nanoparticles in an experimentally induced Alzheimer's disease model. J Drug Target. Epub December 11, 2012.
167. Venishetty VK, Komuravelli R, Kuncha M, Sistla R, Diwan PV. Increased brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles. Nanomedicine. 2013;9(1): 111-121.
168. Jin J, Bae KH, Yang H, et al. In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles. Bioconjug Chem. 2011;22(12):2568-2572.
169. Kakkar V, Kaur IP. Evaluating potential of curcumin loaded solid lipid nanoparticles in aluminium induced behavioural, biochemical and histopathological alterations in mice brain. Food Chem Toxicol. 2011;49(11):2906-2913.
170. Dhawan S, Kapil R, Singh B. Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J Pharm Pharmacol. 2011;63(3):342-351.
171. Montenegro L, Campisi A, Sarpietro MG, et al. In vitro evaluation of idebenone-loaded solid lipid nanoparticles for drug delivery to the brain. Drug Dev Ind Pharm. 2011;37(6):737-746.
172. Alex A, Paul W, Chacko AJ, Sharma CP. Enhanced delivery of lopinavir to the CNS using Compritol-based solid lipid nanoparticles. Ther Deliv. 2011;2(1):25-35.
173. Chattopadhyay N, Zastre J, Wong HL, Wu XY, Bendayan R. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm Res. 2008;25(10):2262-2271.
174. Hsu SH, Wen CJ, Al-Suwayeh SA, Chang HW, Yen TC, Fang JY. Physicochemical characterization and in vivo bioluminescence imaging of nanostructured lipid carriers for targeting the brain: apomorphine as a model drug. Nanotechnology. 2010;21(40):405101.
175. Patel S, Chavhan S, Soni H, et al. Brain targeting of risperidoneloaded solid lipid nanoparticles by intranasal route. J Drug Target. 2011;19(6):468-474.
176. Gupta Y, Jain A, Jain SK. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J Pharm Pharmacol. 2007;59(7):935-940.
177. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Release. 2008;127(2): 97-109.
178. Patel M, Souto EB, Singh KK. Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles. Expert Opin Drug Deliv. 2013;10(7):889-905.
179. World Health Organization. What are the public health implications of global ageing? Available from http://www.who.int/features/qa/42/en/index.html. Accessed December 13, 2013.